STORM Therapeutics raises $56 million Series C for STC-15 trial
Existing investors backed clinical development as the company dosed its first patient in a Phase 2 sarcoma study.
STORM Therapeutics announced a $56 million Series C on April 16, 2026. The capital will support a Phase 2 monotherapy study of its investigational METTL3 inhibitor, STC-15, in selected sarcomas.
M Ventures, Pfizer Ventures, Taiho Ventures, IP Group plc, UTokyo Innovation Platform Co and Fast Track Initiative (FTI) funded the round.
The company said the first patient had been dosed. The trial will assess the treatment’s effects in selected cancers and guide further clinical development.
Use of funds
Advance STC-15 Phase 2 monotherapy study in selected sarcomas